Active substance
Results for the substance cerliponase alfa
1 result
About this active substance
Cerliponase alfa is a recombinant enzyme used for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2), a rare genetic disorder affecting the central nervous system. It replaces the deficient enzyme tripeptidyl peptidase 1 (TPP1), slowing the progression of the disease.
The medication is administered via intraventricular infusion, usually once every two weeks, under the supervision of a specialist. The treatment requires the use of a specially implanted device to deliver the medication directly into the cerebrospinal fluid.
Patients should be closely monitored during and after administration to detect potential side effects, such as allergic reactions, inflammation, or infections at the implant site. It is important for patients to adhere to the treatment schedule and inform their doctor of any unusual symptoms.
Common side effects include fever, vomiting, headache, and irritation at the implant site. In rare cases, severe reactions such as meningitis or anaphylactic reactions may occur. Patients and caregivers should be informed of these risks.
The medication is administered via intraventricular infusion, usually once every two weeks, under the supervision of a specialist. The treatment requires the use of a specially implanted device to deliver the medication directly into the cerebrospinal fluid.
Patients should be closely monitored during and after administration to detect potential side effects, such as allergic reactions, inflammation, or infections at the implant site. It is important for patients to adhere to the treatment schedule and inform their doctor of any unusual symptoms.
Common side effects include fever, vomiting, headache, and irritation at the implant site. In rare cases, severe reactions such as meningitis or anaphylactic reactions may occur. Patients and caregivers should be informed of these risks.